Discovery and exploratory research can identify new antibiotics and biological targets. However, failure rates are high, and funding is insufficient to solve the scientific challenges and attract researchers to antibacterial R&D. Novel methods, including artificial intelligence, have been applied to early-stage research, but these have yet to deliver new antibiotics. The Global Antibiotic Research & Development Partnership (GARDP) is investing in discovery and exploratory research and an R&D education and outreach program. GARDP's efforts, including application of novel R&D methods and new global networks of R&D researchers to develop new antibiotics, is helping address antimicrobial resistance sustainably over the long-term.
机构:
Francis Crick Inst, Mycobacterial Metab & Antibiot Res Lab, London NW1 1AT, England
GlaxoSmithKline, GSK Francis Crick Inst, Linklabs Med Sci & Technol, Stevenage SG1 2NY, EnglandFrancis Crick Inst, Mycobacterial Metab & Antibiot Res Lab, London NW1 1AT, England
Craggs, Peter D.
de Carvalho, Luiz Pedro S.
论文数: 0引用数: 0
h-index: 0
机构:
Francis Crick Inst, Mycobacterial Metab & Antibiot Res Lab, London NW1 1AT, EnglandFrancis Crick Inst, Mycobacterial Metab & Antibiot Res Lab, London NW1 1AT, England